FDAnews
www.fdanews.com/articles/100950-santhera-starts-phase-iib-trial-with-jp-1730

Santhera Starts Phase IIb Trial With JP-1730

November 12, 2007

Swiss drugmaker Santhera Pharmaceuticals and Finland’s Juvantia Pharma have enrolled the first patient in a Phase IIb clinical trial to evaluate JP-1730 for the treatment of Dyskinesia in Parkinson's Disease.

The 152-patient, double-blind, randomized, placebo-controlled, dose-response FJORD study will assess JP-1730's capacity to reduce dyskinetic movements and to extend the anti-Parkinsonian action of levodopa. The safety and efficacy of three escalating doses of JP-1730 will be compared with placebo over a treatment period of 28 days, Santhera said.

Results are expected in the second half of 2008.